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Drug development for complex diseases is shifting from targeting individual proteins or genes
to systems-based attacks targeting dynamic network states. Lee et al. now reveal how the progres-
sive rewiring of a signaling network over time following EGF receptor inhibition leaves triple-
negative breast tumors vulnerable to a second, later hit with DNA-damaging drugs, demonstrating
that time- and order-dependent drug combinations can be more efficacious in killing cancer cells.Aberrant signaling drives the pathological
behavior of cells during tumor develop-
ment. However, signaling networks are
highly complex, involving a large en-
semble of dynamic interactions that flux
in space and time. Thus, to understand
how inappropriate cell decisions arise
and determine the best strategy to modu-
late them requires a global view of cell
signaling network dynamics, underpinned
by both quantitative measurements and
computational modeling (Janes et al.,
2005; Linding et al., 2007). In particular,
it is vital to identify network states or
attractors in cancer cells and to utilize
these to prevent disease progression.
Such understanding holds great pro-
mise for the development of therapeutics
that target systems and networks (‘‘net-
work drugs’’) (Erler and Linding, 2009;
Pawson and Linding, 2008). However,
direct translational impacts of systems
biology studies have so far been scarce
(Huang et al., 2007; Schoeberl et al.,
2009).
In this issue of Cell, Lee et al. (2012)
from Mike Yaffe’s team at MIT harness
the immense power of systems biology
to identify therapeutic strategies against
cancer. Instead of shying away from the
biological complexity, Lee and colleagues
take the bull by the horns, monitoring
the dynamic network response of breast
cancer cells to a set of different clinically
relevant therapeutic agents, including
DNA-damaging reagents and kinase in-
hibitors. The team integrates multipletypes of quantitative data using advanced
computational network modeling and find
that the most effective strategy for killing
aggressive triple-negative breast cancer
(TNBC) cells in vitro and in vivo is a time-
and order-dependent combination of
drugs (Figure 1), specifically, treatment
with the EGF receptor kinase inhibitor er-
lotinib followed by doxorubicin. This
finding has two profound consequences.
First, it demonstrates that drugs such as
kinase inhibitors can push cells toward
a new cellular state, rendering them
vulnerable to other drugs such as DNA-
damaging agents. Second, it shows that
drugs target dynamic molecular networks
and highlights the importance of studying
the dynamics of the system to be tar-
geted, including time dependency and
the order of treatments.
The context-dependent nature of
signaling networks driving cell decisions
was convincingly illustrated in a seminal
paper from Lauffenburger and Yaffe in
2005, which showed that the outcome of
JNK kinase activity on cell fate depends
on the state of the cellular signaling
network prior to its activation (Janes
et al., 2005). To predict cell behavior, it
is thus a requirement to asses temporal-
and/or state-based network dynamics in
response to perturbations such as those
induced by anticancer drugs. Yaffe’s
paper in the current issue of Cell takes
this to the next level, showing that
highly effective tumor targeting strategies
can be developed with an a priori knowl-Celledge of the multivariate nature of the
network being targeted. Importantly, the
work clearly demonstrates that network
activity, and not expression levels of
EGFR, is a marker for response to treat-
ment. Understanding how a network
will respond to a particular drug is there-
fore essential to find the best strategy
to target it. This has deep implications
for the deployment of biomarkers, and
translating such network-based bio-
markers into the clinic will clearly be
a challenge (Erler and Linding, 2009).
Though our understanding of adaptation,
compensation, and network rewiring is
currently not sufficient to allow ab initio
predictions of the cellular response in
any cell type, it is now clear that attractor
states in networks of cancer cells (for
example, through sustained EGFR in-
hibition) can open up for second-phase
attacks using DNA-damaging drugs to
drive apoptosis.
Why have such studies been, until
recently, lacking in the drug development
field? Put simply, there are two strictly
required aspects that have been missing.
First, and perhapsmost importantly, there
has been a lack of systems approaches to
understanding and targeting disease,
with most studies focusing on individual
targets and the identification of specific
mutations, without investigating the im-
pact of these on signaling and other
molecular networks. Second, only in the
last decade has it become technologi-
cally feasible to monitor thousands of149, May 11, 2012 ª2012 Elsevier Inc. 731
Figure 1. Targeting Systems Dynamics in Cancer
Lee et al. used a combinatorial, time-, and order-dependent therapy to effectively induce apoptosis in
triple-negative breast cancer cells. The most effective therapy, which consisted of a combination of
erlotinib (drug A) 4 hr before administration of doxorubicin (drug B), showed significantly more potent
efficacy than administrating erlotinib alone (top), erlotinib and doxorubicin at the same time (middle), or
erlotinib 4 hr after doxorubicin (bottom). The authors show that this time and order dependency is achieved
by erlotinib rewiring the signaling network and pushing the cell toward a state of higher sensitivity to
doxorubicin.
732 Cell 149, May 11, 2012 ª2012 Elsevier Inc.molecular signals embedded in dynamic
signaling networks and to integrate them
computationally in order to gain biologi-
cal insight into drug mechanisms and
efficacy.
The study by Lee et al. highlights the
need to take systematic biochemical
approaches to understand and target
disease effectively and to computationally
integrate molecular and phenotypic data
to model the system under study. Future
studies should address what underlies
the signaling network heterogeneity in
the cell lines that did not respond to the
order- and time-dependent apoptotic
effect of the combinatorial therapy. In
addition, the authors’ current approach
relies on affinity reagents and prior knowl-
edge of the organization of so-called
‘‘pathways.’’ Signaling networks are far
too dynamic and intertwined to be well
described by the classical static ‘‘path-
way’’ framework (Jørgensen and Linding,
2010). Thus, this approach will bias the
performance of the model due to limited
sampling of network states. An alternative
approach would be to perform an ab initio
study in which all network elements were
sampled and monitored using proteome-
wide, mass spectrometry integrated with
multidimensional, quantitative phenotyp-
ing to derive unbiased predictive network
models (Jørgensen and Linding, 2010).
We predict that such strategies in-
tegrating multiple types of quantitative
molecular and phenotypic data to study
network dynamics will dramatically
impact our understanding of cells and
disease.
The age of ‘‘network medicine’’ has
clearly begun. In addition to supporting
the original definition of network medicine
(Pawson and Linding, 2008) as a pharma-
cology that defines both the network
connectivity and dynamics as compo-
nents of drug targets, the paper is argu-
ably one of the first examples of systems
biology reallymaking a difference in trans-
lational research and beyond. As disease
researchers, we must consider network
states, and this and other studies serve
as a model for a new generation of cancer
biologists. The work by Lee et al. is
groundbreaking in its demonstration that
the principles of order and time are essen-
tial to the development of effective thera-
pies against complex diseases. We are
convinced that approaches such as those
used by Lee et al., in combination with
large-scale profiling of individual patients
(Chen et al., 2012), will drive the discovery
of powerful effective drug combinations
and new therapeutic strategies. Once we
learn howcells become rewired and reach
new network states, it will be much more
feasible to force tumor cells out of these
pathological states in order to kill or
‘‘normalize’’ them through drug-induced
dynamic rewiring of signaling networks.
It remains to be seen whether these
approaches will be effective in clinical
trials. But for now, the future looks very
bright for network medicine.
ACKNOWLEDGMENTS
Thanks to Pau Creixell (C-SIG, DTU) for essential
input and help with the manuscript and creationof the figure. R.L. is supported by a Sapere Aude
Starting Grant from The Danish Council for Inde-
pendent Research, a Lundbeck Foundation Group
Leader Fellowship, and a Career Development
Award from Human Frontier Science Program.
J.T.E. is supported by a Hallas Møller Stipend
from the Novo Nordisk Foundation. See http://
www.networkbio.org, http://www.lindinglab.org,
and http://www.erlerlab.org for more information
on cancer-related network biology.REFERENCES
Chen, R., Mias, G.I., Li-Pook-Than, J., Jiang, L.,
Lam, H.Y., Chen, R., Miriami, E., Karczewski,
K.J., Hariharan, M., Dewey, F.E., et al. (2012).
Cell 148, 1293–1307.
Erler, J., and Linding, R. (2009). J. Pathol. 220,
290–296.
Huang, P.H., Mukasa, A., Bonavia, R., Flynn, R.A.,
Brewer, Z.E., Cavenee, W.K., Furnari, F.B., andCellWhite, F.M. (2007). Proc. Natl. Acad. Sci. USA
104, 12867–12872.
Janes, K.A., Albeck, J.G., Gaudet, S., Sorger, P.K.,
Lauffenburger, D.A., and Yaffe, M.B. (2005).
Science 310, 1646–1653.
Jørgensen, C., and Linding, R. (2010). Curr. Opin.
Genet. Dev. 20, 15–22.
Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M.,
Sorger, P.K., MacBeath, G., and Yaffe, M.B.
(2012). Cell 149, this issue, 780–794.
Linding, R., Jensen, L.J., Ostheimer, G.J., van
Vugt, M.A., Jørgensen, C., Miron, I.M., Diella, F.,
Colwill, K., Taylor, L., Elder, K., et al. (2007). Cell
129, 1415–1426.
Pawson, T., and Linding, R. (2008). FEBS Lett. 582,
1266–1270.
Schoeberl, B., Pace, E.A., Fitzgerald, J.B., Harms,
B.D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas,
V., Bukhalid, R., et al. (2009). Sci. Signal. 2, ra31.RNP Export by Nuclear Envelope Budding
Emily M. Hatch1 and Martin W. Hetzer1,*
1Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA
*Correspondence: hetzer@salk.edu
DOI 10.1016/j.cell.2012.04.018
Nuclear export of mRNAs is thought to occur exclusively through nuclear pore complexes. In this
issue ofCell, Speese et al. identify an alternate pathway formRNAexport inmuscle cells where ribo-
nucleoprotein complexes involved in forming neuromuscular junctions transit the nuclear envelope
by fusing with and budding through the nuclear membrane.The canonical model of macromolecular
trafficking between the nucleus and the
cytoplasm stipulates that all communica-
tion between these compartments occurs
exclusively via the nuclear pore com-
plexes (NPCs), which perforate the
double membrane of the nuclear enve-
lope (NE). Import and export through the
NPCs relies on specific signal sequences
and associated transport factors. Regu-
lated transport through the NPCs main-
tains proper gene expression by ensuring
that only correctly formed mRNAs access
the translation machinery in the cyto-
plasm. In this issue of Cell, Speese et al.
(2012) add a new wrinkle to the process
and show that large RNP granules formedin Drosophila muscle cells during syn-
aptogenesis are exported by budding
through theNE instead of passing through
the NPCs. (Figure 1).
Newly transcribed mRNAs assemble
into large ribonucleoprotein complexes
prior to export from the nucleus. These
particles vary in size and some exceed
the NPC diameter (Gru¨nwald et al., 2011).
One of the largest known RNPs, the
Balbiani ring particle, overcomes this diffi-
culty by undergoing extensive remodeling
to conform to theNPCdiameter (Daneholt,
2001). In addition, certain viruses export
large particles by using a mechanism that
completely bypasses the NPCs. Herpes
viruses assemble large capsids in thenucleus that bind to the inner nuclear
membrane, dissolve the lamina, a protein
network that supports the nucleus, and
bud into the perinuclear space between
the inner and outer nuclear membranes
(INM and ONM). From there the capsid
buds fusewith theONM to exit to the cyto-
plasm (Johnson and Baines, 2011). Now,
Speese and colleagues suggest that the
virus may have co-opted a mechanism
already used for RNP transport.
Signaling at neuromuscular junctions
(NMJs) during Drosophila development
involves the internalization and cleavage
of the wnt receptor DFrizzled2. Process-
ing of DFrizzled2 to DFz2C is required
for proper synapse formation, but how149, May 11, 2012 ª2012 Elsevier Inc. 733
